Health ❯ Healthcare ❯ Patient Outcomes

Adverse Events

Gastrointestinal Issues Clinical Study Results Therapeutic Efficacy Major Bleeding Death Investigations Long-term Follow-up Safety Profiles Bleeding Risk Never Events Mortality Rates Treatment Tolerability

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Phase 3 trials are set to begin this quarter following 48-week topline data showing large placebo-adjusted weight loss.

TCT 2025: Stent‑Sparing Balloons Match DES at One Year as Lower‑Cost Alternatives Rival IVL

ESC Trials Recast Antiplatelet Strategies After PCI and CABG